BACKGROUND: The standard treatment for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancer (BC) is still controversial. Our aim was to assess the prognostic role of tumour-infiltrating lymphocytes (TILs) in patients with stage pT1a-b HER2-positive BC. PATIENTS AND METHODS: Haematoxylin and eosin slides from node-negative, pT1a-b HER2-positive BC surgical specimens were retrieved from pathology archives to assess TILs and their association with outcome. RESULTS: TILs were evaluated in 205 patients with HER2-positive, pT1a-b tumours, who underwent breast surgery between 1997 and 2009 at the European Institute of Oncology. At a median follow-up of 11 years, we did not observe any association between the presence of TILs, either assessed as a continuous or dichotomous variable (<50 versus ≥ 50%), and outcome. Within the subgroup of patients with pT1a tumours who did not receive any adjuvant therapy (36/97 patients), the rate of disease-free survival events was lower in lymphocyte-predominant BC (LPBC) as compared with non-LPBC patients (p = 0.066). CONCLUSIONS: TILs cannot be used as a prognostic biomarker in pT1a-b HER2-positive BC. Additional biomarkers are needed for selecting patients with stage I HER2-positive BC who candidate to adjuvant therapy de-escalation.
Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer / C. Criscitello, C. Bagnardi, G. Pruneri, A. Vingiani, A. Esposito, N. Rotmensz, G. Curigliano. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 87(2017 Dec), pp. 164-171.
|Titolo:||Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer|
|Parole Chiave:||HER2; Stage pT1a–b breast cancer; Tumour-infiltrating lymphocytes; Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Receptor, ErbB-2; Risk Factors; Time Factors; Treatment Outcome|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||dic-2017|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.ejca.2017.10.011|
|Appare nelle tipologie:||01 - Articolo su periodico|